Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mingjie Yu

Showing results (11-20 of 32) with videos related to

Pageof 4
Sort By:
Translational Oncology|August 19, 2025
High-dose furmonertinib plus bevacizumab in EGFR-mutant non-small cell lung cancer with brain metastases after resistance to third-generation EGFR-TKIs: A retrospective studyYin Pan, Meichen Li, Mingjie Yu, et al.
Drug Design, Development and Therapy|March 23, 2026
Therapeutic Monitoring of Polymyxin B in Critically Ill Patients with Carbapenem-Resistant Organisms: Evaluation Based on Steady-State Trough and Peak ConcentrationsJun Yang, Yunpei Zhao, Linli Xie, et al.
Journal of Cancer Research and Clinical Oncology|May 6, 2023
Diagnostic and prognostic value of pretreatment PET/CT in extranodal natural killer/T-cell lymphoma: a retrospective multicenter studyMingjie Yu, Zegeng Chen, Zhao Wang, et al.
Biomedical Chromatography : BMC|September 9, 2022
Establishment and validation of a LC-MS/MS method for the determination of anlotinib in human plasma: Application to therapeutic drug monitoringMingjie Yu, Zaiming Liang, Lirong Xiong, et al.
Frontiers in Pharmacology|March 27, 2025
Population pharmacokinetics of polymyxin B in critically ill patients with carbapenem-resistant organisms infections: insights from steady-state trough and peak plasma concentrationJun Yang, Mingjie Yu, Yu Gan, et al.
NPJ Precision Oncology|December 1, 2025
Efficacy and safety with aumolertinib plus anlotinib for untreated EGFR-mutant NSCLC with brain metastasesJing Chen, Yin Pan, Meichen Li, et al.
Journal of Global Antimicrobial Resistance|March 23, 2024
Corrigendum to "Therapeutic drug monitoring of imipenem/cilastatin and meropenem in critically ill adult patients" [Journal of Global Antimicrobial Resistance 36 (2024) 252-259]Xi You, Qing Dai, Jing Hu, et al.
Frontiers in Pharmacology|March 2, 2023
Factors influencing plasma concentration of voriconazole and voriconazole- N-oxide in younger adult and elderly patientsLin Cheng, Zaiming Liang, Fang Liu, et al.
Journal of Global Antimicrobial Resistance|January 25, 2024
Therapeutic drug monitoring of imipenem/cilastatin and meropenem in critically ill adult patientsXi You, Qing Dai, Jing Hu, et al.
Optics Letters|September 13, 2024
Flexible fabrication of core/shell nanoparticles for tailored infrared emissivity on aluminum via femtosecond laser self-depositionQuanxing Zhai, Wenqi Gong, Mingjie Yu, et al.
Pageof 4

Showing results (11-20 of 32) with videos related to

Sort By:
Pageof 4
Translational Oncology|August 19, 2025
High-dose furmonertinib plus bevacizumab in EGFR-mutant non-small cell lung cancer with brain metastases after resistance to third-generation EGFR-TKIs: A retrospective studyYin Pan, Meichen Li, Mingjie Yu, et al.
Drug Design, Development and Therapy|March 23, 2026
Therapeutic Monitoring of Polymyxin B in Critically Ill Patients with Carbapenem-Resistant Organisms: Evaluation Based on Steady-State Trough and Peak ConcentrationsJun Yang, Yunpei Zhao, Linli Xie, et al.
Journal of Cancer Research and Clinical Oncology|May 6, 2023
Diagnostic and prognostic value of pretreatment PET/CT in extranodal natural killer/T-cell lymphoma: a retrospective multicenter studyMingjie Yu, Zegeng Chen, Zhao Wang, et al.
Biomedical Chromatography : BMC|September 9, 2022
Establishment and validation of a LC-MS/MS method for the determination of anlotinib in human plasma: Application to therapeutic drug monitoringMingjie Yu, Zaiming Liang, Lirong Xiong, et al.
Frontiers in Pharmacology|March 27, 2025
Population pharmacokinetics of polymyxin B in critically ill patients with carbapenem-resistant organisms infections: insights from steady-state trough and peak plasma concentrationJun Yang, Mingjie Yu, Yu Gan, et al.
NPJ Precision Oncology|December 1, 2025
Efficacy and safety with aumolertinib plus anlotinib for untreated EGFR-mutant NSCLC with brain metastasesJing Chen, Yin Pan, Meichen Li, et al.
Journal of Global Antimicrobial Resistance|March 23, 2024
Corrigendum to "Therapeutic drug monitoring of imipenem/cilastatin and meropenem in critically ill adult patients" [Journal of Global Antimicrobial Resistance 36 (2024) 252-259]Xi You, Qing Dai, Jing Hu, et al.
Frontiers in Pharmacology|March 2, 2023
Factors influencing plasma concentration of voriconazole and voriconazole- N-oxide in younger adult and elderly patientsLin Cheng, Zaiming Liang, Fang Liu, et al.
Journal of Global Antimicrobial Resistance|January 25, 2024
Therapeutic drug monitoring of imipenem/cilastatin and meropenem in critically ill adult patientsXi You, Qing Dai, Jing Hu, et al.
Optics Letters|September 13, 2024
Flexible fabrication of core/shell nanoparticles for tailored infrared emissivity on aluminum via femtosecond laser self-depositionQuanxing Zhai, Wenqi Gong, Mingjie Yu, et al.
Pageof 4